Degenerative diseases such as osteoarthritis, diabetes, heart disease, and liver cirrhosis have become major global health burdens. Stem cell therapy, particularly using Mesenchymal Stem Cells (MSCs), has emerged as a promising approach to address these conditions. This article scientifically discusses the potential of stem cell therapy for various degenerative conditions, its mechanisms of action, and the challenges that still need to be faced.
What Are Degenerative Diseases?
Degenerative diseases are conditions in which bodily tissues or organs experience progressive functional decline over time. Common examples include:
Osteoarthritis: Damage to joint cartilage causing pain and stiffness.
Diabetes Mellitus: Glucose metabolism disorders resulting from insulin resistance or pancreatic beta-cell damage.
Ischemic Heart Disease: Reduced blood flow to the heart caused by narrowed blood vessels.
Liver Cirrhosis: Scar tissue in the liver resulting from chronic inflammation.
How Do Stem Cells Work in Addressing Degenerative Diseases?
MSCs provide therapeutic effects through various mechanisms:
Immune System Modulation: MSCs have the ability to readjust an overactive immune system. They release various signaling molecules that reduce inflammation and prevent further tissue damage. In liver disease, MSCs modulate T cells, B cells, and macrophages to reduce the chronic inflammation that causes fibrosis.
Paracrine Effect: MSCs release various bioactive molecules—including growth factors, cytokines, and exosomes—that:
Reduce inflammation.
Promote the formation of new blood vessels (angiogenesis).
Inhibit cell death (apoptosis).
Reduce scar tissue formation (fibrosis).
In heart disease, this paracrine effect helps repair damaged heart muscle function without the stem cells needing to transform into actual heart cells.
Tissue Regeneration: MSCs can differentiate into various cell types, including cartilage cells, muscle cells, and liver cells, thereby helping to repair damaged tissues.
Mitochondrial Protection: Recent research indicates that MSCs can improve mitochondrial function in damaged cells, helping to restore cellular metabolism.
Potential of Stem Cell Therapy for Various Degenerative Diseases
1. Osteoarthritis and Orthopedic Diseases
Osteoarthritis is the most widely researched condition in orthopedic stem cell therapy. Out of 169 identified clinical trials, the most common doses used are $1 \times 10^7$, $2 \times 10^7$, and $5 \times 10^7$ cells. The most widely utilized cell sources are:
Adipose tissue (AD-MSCs): 47 clinical trials (27.81%)
Bone marrow (BM-MSCs): 39 clinical trials (23.07%)
Umbilical cord (UC-MSCs): 27 clinical trials (15.98%)
In Indonesia, stem cell therapy for orthopedics is regulated under the Decree of the Minister of Health No. 1359 of 2024. Covered indications include osteoarthritis, critical bone defects, ligament injuries, spinal cord injuries, and intervertebral disc degeneration.
2. Diabetes Mellitus and Its Complications
Recent research shows that MSCs have the potential to address diabetes and its complications.
Type 2 Diabetes: A retrospective study of 301 type 2 diabetes patients who received umbilical cord MSC infusions showed improvements in glycemic control and systemic inflammatory markers. Umbilical cord MSCs are a preferred choice due to their higher proliferation rate, strong paracrine effects, and non-invasive collection process without ethical controversy.
Diabetic Nephropathy (Kidney Complication): The NEPHSTROM clinical trial (Phase 1b/2a) on 16 type 2 diabetes patients with progressive diabetic nephropathy showed promising results. Patients receiving MSCs experienced a significant slowdown in kidney function decline compared to placebos ($p < 0.05$) with no serious side effects.
Diabetic Retinopathy (Eye Complication): MSCs exhibit neuroprotective effects and blood-retina barrier protection through the secretion of neurotrophic factors such as BDNF and GDNF. Exosome therapy from MSCs is also emerging as a novel approach to address this complication.
3. Heart Disease
Various clinical trials have explored MSC therapy for heart disease.
Ischemic Heart Failure: Combined data from the SCIENCE and Danish ASC trials (totaling 214 patients) demonstrated that adipose tissue-derived MSC therapy is safe and can improve the quality of life for ischemic heart failure patients.
Phase III Clinical Trial: Conducted on 537 patients using mesenchymal precursor cells, showing significant quality of life improvements lasting up to 12 months.
Diabetic Patients with Heart Disease: The ACESO-IHD trial (Phase I/II) on 26 diabetic patients with ischemic heart disease showed that MSC infusions are safe and potentially prevent blood vessel re-occlusion. All re-occlusion events occurred in the placebo group, with a Number Needed to Treat of 4.5 to prevent one event.
4. Liver Cirrhosis
Liver cirrhosis is the end-stage of liver fibrosis caused by chronic inflammation. MSCs offer a novel approach through:
Immune modulation: Reducing the activation of hepatic stellate cells that cause fibrosis.
Anti-fibrotic effects: Suppressing excessive extracellular matrix production.
Hepatocyte regeneration: MSCs can differentiate into liver cells or stimulate the regeneration of existing liver cells.
However, due to the risk of tumorigenesis from MSCs, researchers are shifting toward exosome therapy—nano-vesicles released by MSCs—which are considered safer.
Exosome Therapy: Cell-Free Alternatives
Exosomes are nano-vesicles released by MSCs that act as biological "message packages." This approach offers several advantages:
Lower risk: No risk of tumor formation or immune rejection.
Stable: Easier to store and distribute.
Able to cross the blood-brain barrier: Opening opportunities for neurodegenerative diseases.
In liver disease, MSC-derived exosomes exhibit protective effects via various pathways, including autophagy regulation, oxidative stress reduction, and inflammation modulation.
Challenges and Limitations
Lack of Standardization: Out of 449 clinical trials for orthopedic conditions, 57.99% did not clearly state the dosage used, and 27.22% did not state the cell source. This highlights the urgent need for standardized treatment protocols.
High Costs: Stem cell therapy remains very expensive and unaffordable for the majority of patients.
Long-Term Effects: The long-term effects of stem cell therapy are not yet fully understood, necessitating follow-up studies with longer monitoring periods.
Regulatory Differences: Regulations vary by country. In Indonesia, stem cell therapy is regulated by the Ministry of Health and must be performed in licensed medical facilities with official permits.
Conclusion
Stem cell therapy offers new hope for sufferers of degenerative diseases who do not respond to conventional treatments. With its ability to reduce inflammation, modulate the immune system, and support tissue regeneration, this therapy can alter disease progression and improve patients' quality of life.
However, it is important to remember that this therapy is still evolving. Patients should choose legal and trusted healthcare facilities, be guided by specialist physicians, and maintain realistic expectations regarding treatment outcomes.
This article is prepared for educational purposes. Always consult with a specialist physician before deciding to undergo stem cell therapy.
